Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2026)

Eli Lilly (LLY) has reported Long-Term Deferred Tax for 10 consecutive years, with $11.4 billion the latest figure, recorded in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $11.4 billion, up 32.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 billion (up 32.39% YoY), and the FY2025 annual result was $10.0 billion, up 24.47% from the prior year.
• Long-Term Deferred Tax was $11.4 billion for Q1 2026 at Eli Lilly, up from $10.0 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $11.4 billion in Q1 2026 and troughed at $2.4 billion in Q2 2022.
• Average Long-Term Deferred Tax over 5 years is $6.1 billion, with a median of $5.6 billion recorded in 2024.
• Year-over-year, Long-Term Deferred Tax decreased 11.33% in 2022 and surged 96.12% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $2.8 billion in 2022, then surged by 96.12% to $5.5 billion in 2023, then soared by 46.08% to $8.0 billion in 2024, then rose by 24.47% to $10.0 billion in 2025, then increased by 13.97% to $11.4 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $11.4 billion in Q1 2026, $10.0 billion in Q4 2025, and $9.0 billion in Q3 2025.